Fresenius Medical Care, the world’s leading provider of products and services for people with chronic kidney failure, is excellently positioned for continued, sustainable growth. At today’s virtual-only Capital Markets Day, management presented the company’s new growth strategy and a new medium-term outlook for the coming five years to analysts and investors.
Fresenius Medical Care aims to much more closely mesh, over the entire path of the illness, the still highly fragmented treatments provided to chronic and critical kidney disease patients. For this purpose, the company will leverage even more effectively its core competencies in the innovation of products, operating outpatient facilities, standardizing medical procedures and efficiently coordinating patients.
The new strategy embraces three major areas. The first area, the Renal Care Continuum, puts dialysis products and services at its core and is enhanced by four components:
New renal care models: Using digital technologies such as artificial intelligence and the capability to analyze huge amounts of data, Fresenius Medical Care is working to develop new forms of renal therapy. These include, for example, personalized medicine or holistic home care.
Value-based care: Drawing on its comprehensive experience in disease management, the company will push forward with the transition from a fee-for-service payment model to pay-for-performance models, in order to offer care that is even better and is also sustainably affordable.
Chronic kidney disease and transplantation: Fresenius Medical Care’s offerings in the area of value-based care models will be expanded beyond dialysis to the treatment of chronic kidney disease as well as an active role in the area of kidney transplantation.
Renal care innovations: The company will continue to advance its development of renal care innovations and invest in start-ups and early-stage companies in the healthcare sector.
The second area is Critical care solutions. Fresenius Medical Care will extend its critical care portfolio to other extracorporeal intensive care therapy areas, such as the treatment of heart, lung and multi-organ failure.
The third area is Complementary assets. To leverage its existing network and create an additional basis for future growth, the company will further expand its network of complementary assets through partnerships, investments and acquisitions.
The new strategy is embedded in the company’s Global Sustainability Program, which was launched last year. This program is under the direct responsibility of the Chief Executive Officer, and Management Board compensation will be oriented to it.
Together with the new strategy, Fresenius Medical Care is announcing a new medium-term outlook through 2025. During the next five years, in constant currency and excluding special items, the company expects annual average increases in the mid-single-digit percentage range for revenue and in the upper-single-digit percentage range for net income.
Rice Powell, Chief Executive Officer of Fresenius Medical Care, said during the opening of the Capital Markets Day: “The new strategy is our next logical step. It’s the next step up from our four core competencies, it’s a step up for our network – and it’s a step in our quest for even more valuable solutions for our patients as well as for payors and health care systems around the world.”
Presentations and other information material given at the Capital Markets Day will be available soon at: www.freseniusmedicalcare.com/en/investors/events-presentations/capital-markets-day/
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.
Fresenius Medical Care North America announced a partnership with Livongo, the leading Applied Health Signals company in the U.S. This will enable the company to better deliver targeted, real-time care coordination services to patients with late-stage chronic kidney disease (CKD) under value based care agreements with insurance providers and the federal government, as well as manage their comorbidities such as diabetes and hypertension. By deploying innovative technologies and services, the partnership allows patients to receive personalized interventions including remote monitoring, biometrics, education, nutrition, weight management, and emotional support, with the goal to improve outcomes, slow progression of CKD, and reduce the overall cost of care. With earlier intervention, the company also seeks to increase optimal dialysis starts, as well as offer earlier evaluation of transplantation and home dialysis options.
Quirónsalud, the Spanish hospital group that is part of Fresenius Helios, has signed an agreement with Vincci Hotels to offer health care to guests in all accommodations in Spain. The service includes 24/7 medical assistance, either by video call, in person or by a doctor’s visit in the hotel, if necessary. This service is offered in several languages to meet the demands from international guests.
Quirónsalud, the Spanish hospital group that is part of Fresenius Helios, has signed an agreement with Vincci Hotels to offer health careto guests in all accommodations in Spain. The service includes 24/7 medical assistance, either by video call, in person or by a doctor’s visit in the hotel, if necessary. This service is offered in several languages to meet the demands from international guests.
Fresenius Medical Care North America and the health insurer Humana are broadening their collaboration. The goal is improved, better coordinated and more holistic care for eligible members, for example through expanded access to CKD care coordination services and transitional care units. In addition, the existing clinical network contract, which provides eligible members with access to dialysis at more than 2,600 Fresenius Kidney Care clinics, is being implemented as a value-based payment model. This means that reimbursement will be based on meeting agreed quality improvement and patient outcome goals.
Fresenius Medical Care, the world’s leading provider of products and services for people with chronic kidney failure, today announced publication of its 2020 Global Annual Medical Report. Titled “The Power of Ideas: Ingenuity, Optimism, and the Future of Global Healthcare,” it advances the worldwide conversation about the continuing evolution of healthcare and underlines the role Fresenius Medical Care can play in transforming care for chronically ill patients.
“This year’s report focuses on the ideas, ingenuity and optimism that are transforming healthcare,” said Franklin W. Maddux, MD, Global Chief Medical Officer of Fresenius Medical Care. “We look at ways to enhance patient choice, new frontiers in connected health, the promise of artificial intelligence, and other important topics including our global response to COVID-19. Our 2020 report also shows the remarkable diversity of people behind the ideas that are helping us evolve our healthcare systems to recognize the unique lifetime journey of each kidney disease patient.”
The 2020 Global Annual Medical Report comprises 24 chapters by nearly 40 authors from across the company, representing some of Fresenius Medical Care’s best thought leadership on a wide range of topics. These also include precision medicine and genomics, cardioprotective dialysis, value-based care, and transplantation.
Some of the key chapters include:
- Building on Lessons Learned: Activating a Global Pandemic Master Plan
- The Aspirational Role of Artificial Intelligence and Advanced Analytics
- The Power of Precision: Genomics Medicine and Power of Personalization of Kidney Care
- Cardioprotective Dialysis: Improving Cardiovascular Health Through More Personalized Treatment
- Driving Sustainability and Creating Value for Patients in Global Healthcare
- Increasing Access to Transplantation: Lessons from the United States
- Clinical Performance Supports Organized Value-Based Care
- Social Care and Medical Care Become Kidney Care
The 2020 Global Annual Medical Report is published by the Global Medical Office of Fresenius Medical Care. The full report is now available online at:
https://www.freseniusmedicalcare.com/en/about-us/sustainability/medical-responsibility/
Disclaimer
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.
The information and documents contained on the following pages of this website are for information purposes only. These materials do neither constitute an offer nor an invitation to subscribe to or to purchase securities, nor any investment advice or service, and are not meant to serve as a basis for any kind of obligation, contractual or otherwise. Securities may not be offered or sold in the United States of America (“US”) absent registration under the US Securities Act of 1933, as amended, or an exemption from registration. The securities described on the following pages are not offered for sale in the US or to "US persons" (as defined in Regulation S under the US Securities Act of 1933, as amended).
THE FOLLOWING INFORMATION AND DOCUMENTS ARE NOT DIRECTED AT AND ARE NOT INTENDED FOR USE BY (I) PERSONS WHO ARE RESIDENTS OF OR LOCATED IN THE US, CANADA, JAPAN OR AUSTRALIA OR WHO ARE US PERSONS (AS DEFINED IN REGULATION S UNDER THE US SECURITIES ACT OF 1933, AS AMENDED), OR (II) PERSONS IN ANY OTHER JURISDICTION WHERE THE COMMUNICATION OR RECEIPT OF SUCH INFORMATION IS RESTRICTED IN SUCH A WAY THAT PROVIDES THAT SUCH PERSONS SHALL NOT RECEIVE IT. SUCH PERSONS, OR PERSONS ACTING FOR THE BENEFIT OF ANY SUCH PERSONS, ARE NOT PERMITTED TO VISIT THE FOLLOWING PAGES OF THE WEBSITE.
To visit the following parts of this website you must confirm that
(i) you are not a resident of the United States of America, Canada, Japan or Australia or a "US person" (as defined in Regulation S under the US Securities Act of 1933, as amended),
(ii) you are not a person to whom the communication of the information contained on the website is restricted,
(iii) you will not distribute any of the information and documents contained thereon to any such person, and
(iv) you are not acting for the benefit of any such person.
By clicking on the "Accept" button below, you will be deemed to have made this confirmation.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN.
Fresenius today successfully placed bonds with an aggregate volume of €1.0 billion:
- €500 million bonds with a maturity in September 2026 and a coupon of 0.375% were issued at a price of 99.333% resulting in a yield of 0.488%,
- €500 million bonds with a maturity in January 2033 and a coupon of 1.125% were issued at a price of 99.738% resulting in a yield of 1.148%.
The proceeds will be used for general corporate purposes, including refinancing of existing financial liabilities.
The bonds were drawn under the Fresenius European Medium Term Note (EMTN) Program and issued by Fresenius SE & Co. KGaA. The company has applied to the Luxembourg Stock Exchange to admit the bonds to trading on its regulated market.
The envisaged settlement date is September 28, 2020.
This announcement does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, securities to any person in Australia, Canada, Japan, or the United States of America (the “United States”) or in any jurisdiction to whom or in which such offer or solicitation is unlawful. The securities referred to herein may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons, absent registration under the U.S. Securities Act of 1933, as amended (the “Securities Act”) except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. Subject to certain exceptions, the securities referred to herein may not be offered or sold in Australia, Canada or Japan or to, or for the account or benefit of, any national, resident or citizen of Australia, Canada or Japan. The offer and sale of the securities referred to herein has not been and will not be registered under the Securities Act or under the applicable securities laws of Australia, Canada or Japan. There will be no public offer of the securities in the United States.
This announcement is a general information and not a prospectus. Investors should not purchase or subscribe for any securities referred to in this announcement except on the basis of information in the prospectus to be issued by the company in connection with the offering of such securities. Copies of the prospectus will, following publication, be available free of charge from Fresenius SE & Co. KGaA at Else-Kröner Strasse 1, 61352 Bad Homburg, Germany.
This announcement has been prepared on the basis that any offer of securities in any Member State of the European Economic Area (EEA) will be made pursuant to the prospectus prepared by Fresenius SE & Co. KGaA, Fresenius Finance Ireland Public Limited Company and Fresenius Finance Ireland II Public Limited Company in combination with the relevant final terms relating to such securities or pursuant to an exemption under Regulation (EU) 1129/2017 (the Prospectus Regulation) from the requirement to publish a prospectus for offers of securities. Neither Fresenius SE & Co. KGaA, Fresenius Finance Ireland Public Limited Company nor Fresenius Finance Ireland II Public Limited Company have authorized, nor do they authorize, the making of any offer of securities in circumstances in which an obligation arises for Fresenius SE & Co. KGaA, Fresenius Finance Ireland Public Limited Company and Fresenius Finance Ireland II Public Limited Company or any other person to publish or supplement a prospectus for such offer.
This announcement is directed at and/or for distribution in the United Kingdom only to (i) persons who have professional experience in matters relating to investments falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) or (ii) high net worth entities falling within article 49(2)(a) to (d) of the Order (all such persons are referred to herein as “relevant persons”). This announcement is directed only at relevant persons. Any person who is not a relevant person should not act or rely on this announcement or any of its contents. Any investment or investment activity to which this announcement relates is available only to relevant persons and will be engaged in only with relevant persons.
This announcement contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Neither Fresenius SE & Co. KGaA, Fresenius Finance Ireland Public Limited Company nor Fresenius Finance Ireland II Public Limited Company undertake any responsibility to update the forward-looking statements in this announcement.
The information and documents contained on the following pages of this website are for information purposes only. These materials do neither constitute an offer nor an invitation to subscribe to or to purchase securities, nor any investment advice or service, and are not meant to serve as a basis for any kind of obligation, contractual or otherwise. Securities may not be offered or sold in the United States of America (“US”) absent registration under the US Securities Act of 1933, as amended, or an exemption from registration. The securities described on the following pages are not offered for sale in the US or to "US persons" (as defined in Regulation S under the US Securities Act of 1933, as amended).
THE FOLLOWING INFORMATION AND DOCUMENTS ARE NOT DIRECTED AT AND ARE NOT INTENDED FOR USE BY (I) PERSONS WHO ARE RESIDENTS OF OR LOCATED IN THE US, CANADA, JAPAN OR AUSTRALIA OR WHO ARE US PERSONS (AS DEFINED IN REGULATION S UNDER THE US SECURITIES ACT OF 1933, AS AMENDED), OR (II) PERSONS IN ANY OTHER JURISDICTION WHERE THE COMMUNICATION OR RECEIPT OF SUCH INFORMATION IS RESTRICTED IN SUCH A WAY THAT PROVIDES THAT SUCH PERSONS SHALL NOT RECEIVE IT. SUCH PERSONS, OR PERSONS ACTING FOR THE BENEFIT OF ANY SUCH PERSONS, ARE NOT PERMITTED TO VISIT THE FOLLOWING PAGES OF THE WEBSITE.
To visit the following parts of this website you must confirm that
(i) you are not a resident of the United States of America, Canada, Japan or Australia or a "US person" (as defined in Regulation S under the US Securities Act of 1933, as amended),
(ii) you are not a person to whom the communication of the information contained on the website is restricted,
(iii) you will not distribute any of the information and documents contained thereon to any such person, and
(iv) you are not acting for the benefit of any such person.
By clicking on the "Accept" button below, you will be deemed to have made this confirmation.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN.
Fresenius today successfully placed bonds with an aggregate volume of €1.0 billion:
- €500 million bonds with a maturity in September 2026 and a coupon of 0.375% were issued at a price of 99.333% resulting in a yield of 0.488%,
- €500 million bonds with a maturity in January 2033 and a coupon of 1.125% were issued at a price of 99.738% resulting in a yield of 1.148%.
The proceeds will be used for general corporate purposes, including refinancing of existing financial liabilities.
The bonds were drawn under the Fresenius European Medium Term Note (EMTN) Program and issued by Fresenius SE & Co. KGaA. The company has applied to the Luxembourg Stock Exchange to admit the bonds to trading on its regulated market.
The envisaged settlement date is September 28, 2020.
This announcement does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, securities to any person in Australia, Canada, Japan, or the United States of America (the “United States”) or in any jurisdiction to whom or in which such offer or solicitation is unlawful. The securities referred to herein may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons, absent registration under the U.S. Securities Act of 1933, as amended (the “Securities Act”) except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. Subject to certain exceptions, the securities referred to herein may not be offered or sold in Australia, Canada or Japan or to, or for the account or benefit of, any national, resident or citizen of Australia, Canada or Japan. The offer and sale of the securities referred to herein has not been and will not be registered under the Securities Act or under the applicable securities laws of Australia, Canada or Japan. There will be no public offer of the securities in the United States.
This announcement is a general information and not a prospectus. Investors should not purchase or subscribe for any securities referred to in this announcement except on the basis of information in the prospectus to be issued by the company in connection with the offering of such securities. Copies of the prospectus will, following publication, be available free of charge from Fresenius SE & Co. KGaA at Else-Kröner Strasse 1, 61352 Bad Homburg, Germany.
This announcement has been prepared on the basis that any offer of securities in any Member State of the European Economic Area (EEA) will be made pursuant to the prospectus prepared by Fresenius SE & Co. KGaA, Fresenius Finance Ireland Public Limited Company and Fresenius Finance Ireland II Public Limited Company in combination with the relevant final terms relating to such securities or pursuant to an exemption under Regulation (EU) 1129/2017 (the Prospectus Regulation) from the requirement to publish a prospectus for offers of securities. Neither Fresenius SE & Co. KGaA, Fresenius Finance Ireland Public Limited Company nor Fresenius Finance Ireland II Public Limited Company have authorized, nor do they authorize, the making of any offer of securities in circumstances in which an obligation arises for Fresenius SE & Co. KGaA, Fresenius Finance Ireland Public Limited Company and Fresenius Finance Ireland II Public Limited Company or any other person to publish or supplement a prospectus for such offer.
This announcement is directed at and/or for distribution in the United Kingdom only to (i) persons who have professional experience in matters relating to investments falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) or (ii) high net worth entities falling within article 49(2)(a) to (d) of the Order (all such persons are referred to herein as “relevant persons”). This announcement is directed only at relevant persons. Any person who is not a relevant person should not act or rely on this announcement or any of its contents. Any investment or investment activity to which this announcement relates is available only to relevant persons and will be engaged in only with relevant persons.
This announcement contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Neither Fresenius SE & Co. KGaA, Fresenius Finance Ireland Public Limited Company nor Fresenius Finance Ireland II Public Limited Company undertake any responsibility to update the forward-looking statements in this announcement.
The price increase for hospital services in Germany has been set at 2.53% for 2021. As it is subject to negotiations at the state level as well as individual hospital discounts, the final price increase on the individual hospital level will, however, be lower.
The price increase for hospital services in Germany has been set at 2.53% for 2021. As it is subject to negotiations at the state level as well as individual hospital discounts, the final price increase on the individual hospital level will, however, be lower.